Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

imipenem

- PMLiVE

Opdivo approved via UK’s early drug access scheme

Bristol-Myers Squibb’s immunotherapy the first lung cancer drug approved by EAMS

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Get Real! The Rise of Observational Data In Healthcare

Real world data is now becoming a serious research tool for pharma, but just what can it add to the golden standard that is the randomised clinical trial?

Can Cinderella save us?

Pharma should pay into antibiotic resistance fund

Claims stem from the latest UK Review on Antimicrobial Resistance

- PMLiVE

AbbVie remains top of immunology sales

But the threat of biosimilars once again threatens to shake up the leader board

- PMLiVE

Relief as study finds no cardiovascular risk with Januvia

FDA continues to investigate safety of numerous diabetes therapies

- PMLiVE

WHO calls for publication of previously unreported studies

Organisation claims results from clinical trials should be reported within 12 months

- PMLiVE

AstraZeneca and PatientsLikeMe team up on real-world data

Two groups hoping to harness the power of the patient forum network

Can Cinderella save us?

UK government warns over antibiotic resistant deaths

Cabinet Office document says the next 20 years is a crucial period for creating new medicines

- PMLiVE

Novartis cancer pill makes it onto UK early access list

Joins Merck’s melanoma drug Keytruda for the MHRA’s accelerated review programme 

Curbing the rise of drug resistance

The pharma sector could hold the greatest power to address the global threat of antimicrobial resistance

- PMLiVE

Baxter haemophilia drug clears phase III trial

BAX 817 shown to resolve more than 90% of acute bleeds

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links